natgillin/translations-raw huggingface dataset:
hypotension, thrombophlebitis
hipotenzija, tromboflebitis
hypotension, venous thrombosis, pallor, peripheral coldness
hipotenzija, venska tromboza, bljedilo, periferna hladnoća
Hypotension1
hipotenzija1
Hypotension1,4
Hipotenzija1,4
Hypotension; Hypertension; Haemorrhage
hipertenzija, krvarenje
Hypotension; Hypertension; Haemorrhage
hipotenzija, hipertenzija, krvarenje
Hypotension; Hypertension; Haemorrhage
hipotenzija. hipertenzija, krvarenje
Hypotension; Hypertension; Haemorrhage
hipotenzija; hipertenzija; krvarenje
Hypotension; thrombophlebitis; flushing
hipotenzija; tromboflebitis; navale crvenila
Hypotensiona,b, d
Hipotenzijaa,b,d
Hypotensione
hipotenzijae
Hypotensione
kupovanjec)
Hypothermia
hipotermija
hypothermiac, body temperature decreasedc, drug withdrawal syndromec, indurationc
hipothermijac, snižena tjelesna temperatura c, sindrom ustezanjac, induracijac
Hypothyroidis m, hyperthyroidi sm
hipotireoidizam, hipertireoidizam
hypothyroidism
hipotireoza
hypothyroidism (myxoedema)
hipotireoza (miksedem)
Hypothyroidism and/or reduced control of hypothyroidism may occur when orlistat and levothyroxine are co-administered (see section 4.5).
Pri primjeni orlistata istodobno s levotiroksinom može nastupiti hipotireoza i/ili može dovesti do smanjene kontrole hipotireoze (vidjeti odjeljak 4.5).
Hypothyroidism and/or reduced control of hypothyroidism may occur when orlistat and levothyroxine are taken at the same time (see section 4.4).
Uzimaju li se orlistat i levotiroksin istodobno, može nastupiti hipotireoza i/ili može oslabiti kontrola hipotireoze (vidjeti odjeljak 4.4).
Hypothyroidism Blood thyroid stimulating hormone increased‡
hipotireoza povišen tireotropin u krvi
Hypothyroidism has been observed to occur early as well as late during treatment with sunitinib.
Hipotireoza je opažena i u ranoj i u kasnoj fazi liječenja sunitinibom.
Hypothyroidism has been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
Hipotireoza je zabilježena u bolesnika liječenih lenvatinibom (vidjeti dio 4.8 Opis odabranih nuspojava).
Hypothyroidism has been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
U bolesnika liječenih lenvatinibom zabilježena je hipotireoza (vidjeti dio 4.8 Opis odabranih nuspojava).
Hypothyroidism in HIV co-infected patients
Hipotireoza u bolesnika istodobno zaraženih HIV-om
Hypothyroidism in HIV co-infected patients is a very common event and occur in ≥1/10 subjects, particularly when PAS is administered with ethionamide/prothionamide.
Hipotireoza u bolesnika istodobno zaraženih HIV-om je vrlo čest događaj i pojavljuje se u ≥1/10 osoba, posebno kada se paraaminosalicilatna kiselina (PAS) primjenjuje s etionamidom/protionamidom.
Hypothyroidism may develop during treatment with NutropinAq and untreated hypothyroidism may prevent optimal response to NutropinAq.
Hipotireoza se može razviti tijekom liječenja NutropinAq, a neliječena hipotireoza može spriječiti optimalni odgovor na NutropinAq.
Hypothyroidism may develop during treatment with somatropin, and untreated hypothyroidism may prevent optimal response to NutropinAq.
Hipotireoza se može razviti tijekom liječenja somatropinom, a neliječena hipotireoza može spriječiti optimalni odgovor na NutropinAq.
Hypothyroidism resolved in 48 (20%) patients.
Hipotireoza se povukla u 48 (20%) bolesnika.
Hypothyroidism was reported as an adverse reaction in 7 patients (4%) receiving sunitinib across the two cytokine-refractory MRCC studies; in 61 patients (16%) on sunitinib and three patients (<1%) in the IFN- arm in the treatment-naïve MRCC study.
Hipotireoza je prijavljena kao nuspojava u 7 bolesnika (4%) liječenih sunitinibom u oba ispitivanja MRCC-a refraktornog na citokine te u 61 bolesnika (16%) koji je primao sunitinib i tri bolesnika (<1%) koja su primala IFN-α u ispitivanju prethodno neliječenog MRCC-a.
hypothyroidism*
Hipotireoza
hypothyroidism, hyperthyroidism, hyperglycaemiab
hipotireoza, hipertireoza, hiperglikemijab
hypothyroidism, increased blood thyroid stimulating hormone
hipotireoza, povišen tiroidni stimulirajući hormon u krvi
Hypothyroidismc
hipotireozac
Hypothyroidism§, hyperthyroidism§ Diabetes, aggravated diabetes
hipotireoza§, hipertireoza§ šećerna bolest, pogoršanje šećerne bolesti
Hypothyroidism§, Hyperthyroidism§, virilism
hipotireoza§ hipertireoza§, virilizacija
Hypotonia
Hipotonija
Hypotonic reactions or hypotonic-hyporesponsive episodes (HHE)
Hipotonične reakcije ili hipotonično- hiporesponzivne epizode (HHE)
Hypotonic-hyporesponsive episode (collapse or shock-like state)
hipotono-hiporesponzivna epizoda (kolaps ili stanje nalik šoku)
Hypoventilation
hipoventilacija
Hypovolaemic hyponatraemia
Hipovolemična hiponatremija
Hypoxia
hipoksija
Hypoxia Hyperventilation Sinusitis
hipoksija hiperventilacija sinusitis
Hypoxia Wheezing Dyspnoea
hipoksija piskanje dispneja
Hypoxia,
konstipacija,
Hypoxia, cough, dyspnoea
hipoksija, kašalj, dispneja
Hypoxia, tachypnoea, bronchospasm, cough
Hipoksija, tahipneja, bronhospazam, kašalj
Hypoxiab,d Dyspnoeac
Hipoksijab ,d
Hypoxiab,d Dyspnoeac
Hipoksijab,d
Hypromellose
Film ovojnica:
Hypromellose
hipromeloza
Hypromellose (E464) Lactose monohydrate Triacetin (E1518) Titanium dioxide (E171) Red iron oxide (E172)
Film ovojnica: hipromeloza (E464) laktoza hidrat triacetin (E1518) titanijev dioksid (E171) željezov oksid, crveni (E172)
Hypromellose (E464) Magnesium stearate (E572)
Magnezijev stearat (E572)
Hypromellose (E464), Microcrystalline cellulose (E460), Macrogol 40 stearate type I, Anatase titanium dioxide (E171), Yellow Iron Oxide (E172), Red Iron Oxide (E172)
Hipromeloza (E464), mikrokristalična celuloza (E460), makrogol 40 stearat vrste I, titanijev dioksid anatas (E171), željezov oksid žuti (E172), željezov oksid crveni (E172)
Hypromellose (E464), Microcrystalline cellulose (E460), Macrogol 40 stearate type I, Titanium dioxide (E171)
Hipromeloza (E464), mikrokristalična celuloza (E460), makrogol 40 stearat vrste I, titanijev dioksid (E171)
Hypromellose 2208
hipromeloza 2208
Hypromellose acetate succinate Sucrose
hipromeloza hipromelozaacetatsukcinat saharoza
Hypromellose acetate succinate Sucrose
hipromelozaacetatsukcinat saharoza
Hypromellose acetate succinate, medium grade Lactose monohydrate
Hipromeloza acetat sukcinat, srednja vrijednost
Hypromellose Macrogol (8000)
Hipromeloza Makrogol (8000)
Hypromellose Magnesium stearate
hipromeloza magnezijev stearat
Hypromellose Microcrystalline cellulose Mannitol
hipromeloza mikrokristalična celuloza manitol
Hypromellose Polysorbate 80
hipromeloza polisorbat 80
Hypromellose Talc
Hipromeloza Talk
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), carnauba wax.
Hipromeloza, propilenglikol, titanijev dioksid (E171), željezov oksid, crni (E172), željezov oksid, crveni (E172), željezov oksid, žuti (E172), karnauba vosak.
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), iron oxide black (E172), carnauba wax.
Hipromeloza, propilenglikol, titanijev dioksid, (E171) željezov oksid, crveni (E172), željezov oksid, crni (E172), karnauba vosak.
HyQvia 100 mg/ml infusion for subcutaneous use Human normal immunoglobulin
HyQvia 100 mg/ml infuzija za potkožnu primjenu normalni ljudski imunoglobulin
HyQvia 100 mg/ml solution for infusion for subcutaneous use
HyQvia 100 mg/ml otopina za infuziju za potkožnu primjenu
HyQvia 100 mg/ml solution for infusion for subcutaneous use Human normal immunoglobulin
HyQvia 100 mg/ml otopina za infuziju za potkožnu primjenu normalni ljudski imunoglobulin
HyQvia administration scheme
Shema primjene lijeka HyQvia
HyQvia contains two solutions for infusion (drip) under the skin (subcutaneous or SC infusion).
HyQvia sadrži dvije otopine za infuziju (drip) pod kožu (potkožna ili s.c. infuzija).
HyQvia has to be infused under the skin (subcutaneous or SC administration).
Infuzija lijeka HyQvia mora se dati pod kožu (potkožna ili s.c. primjena).
HyQvia is a dual vial unit containing: a solution of recombinant human hyaluronidase (Step 1 of HyQvia/Infuse first) and a solution of human normal immunoglobulin 10% (Step 2 of HyQvia/Infuse second).
HyQvia je jedinica s dvostrukom bočicom koja sadrži: otopinu rekombinantne ljudske hijaluronidaze (1. korak za lijek HyQvia/Infundirati prvo po redu) i otopinu normalnog ljudskog imunoglobulina 10% (2. korak za lijek HyQvia/Infundirati drugo po redu).
HyQvia is supplied as a pack containing:
HyQvia je dostupna kao pakiranje koje sadrži:
HyQvia is used as ‘replacement therapy’ to treat: primary immunodeficiency syndromes (PID, when patients are born with an inability to produce enough antibodies); low levels of antibodies in the blood in patients who have chronic lymphocytic leukaemia or myeloma (two cancers affecting different types of white blood cell) and who have frequent infections.
Lijek HyQvia primjenjuje se kao „nadomjesna terapija” za liječenje: sindroma primarne imunodeficijencije (PID se javlja u bolesnika rođenih s nemogućnošću stvaranja dovoljno protutijela); niske razine protutijela u krvi bolesnika s kroničnom limfocitnom leukemijom ili mijelomom (dvjema vrstama raka koje zahvaćaju bijele krvne stanice) i bolesnika s učestalim infekcijama.
HyQvia Median (95% Cl)
HyQvia Medijan (95%-tni IP)
HZC102871 integrated
HZC102871 zajedno
HZC102970 and
HZC102970 i
HZC112206 evaluated the efficacy of fluticasone furoate/vilanterol 46 /22 micrograms [n=206] and fluticasone furoate/vilanterol 92/22 micrograms [n=206] compared with FF 92 micrograms [n=206], vilanterol
Ispitivanjem HZC112206 ocjenjivala se djelotvornost flutikazonfuroata/vilanterola od 46/22 mikrograma [n=206] i flutikazonfuroata/vilanterola od 92/22 mikrograma [n=206] u odnosu na flutikazonfuroat od
HÄLSA Pharma GmbH Nikolaus Dürkopp Straße 4a D-33602 Bielefeld Germany
HÄLSA Pharma GmbH Nikolaus Dürkopp Straße 4a D-33602 Bielefeld Njemačka
Hôpital Xavier Arnozan Avenue du Haut Lévèque 33600 Pessac (Bordeaux) France
Hôpital Xavier Arnozan Avenue du Haut Lévèque 33600 Pessac (Bordeaux) Francuska
i 48 weeks of double-blind tenofovir disoproxil fumarate followed by 192 weeks open-label.
i 48 tjedana dvostruko slijepog tenofovirdizoproksilfumarata nakon čega je slijedilo 192 tjedna otvorenog liječenja.
I am on Lysodren (mitotane) treatment
Ja se liječim Lysodrenom (mitotan)
I am under anticoagulation treatment with Xarelto (rivaroxaban)
Ja sam na antikoagulantnoj terapiji lijekom Xarelto (rivaroksaban)
I don’t know how to do a subcutaneous injection.
Ne znam kako primijeniti potkožnu injekciju.
i e.g. haemarthrosis, muscle haemorrhage
i npr. hemartroza, krvarenje mišića
I IntronA (3 MIU 3 times a week)
I IntronA (3 milijuna IU triput na tjedan)
I-03012 Anagni-Frosinone - Italy
I-03012 Anagni-Frosinone - Italija
I-04010 Borgo San Michele (Latina) Italy
I-04010 Borgo San Michele (Latina) Italija
I-10044 Pianezza Italy
I-10044 Pianezza Italija
I-21040 Origgio / VA Tel: + 39-02-96 541
I-21040 Origgio / VA
I-21040 Origgio / VA Tel: + 39-02-96 541
I-21040 Origgio / VA Tel: + 39 02 96541
I-36100 Vicenza(VI) - Italy
I-36100 Vicenza(VI) - Italija
I-43056 San Polo di Torrile, Parma Italy
I-43056 San Polo di Torrile, Parma Italija
I-70026 Modugno (Bari) Italy
I-70026 Modugno (Bari) Italija
I-80058 Torre Annunziata - Napoli Italy
I-80058 Torre Annunziata - Napoli Italija
I-80058 Torre Annunziata/NA Italy
I-80058 Torre Annunziata/NA Italija
I-Neb AAD
I Neb AAD
I-Neb AAD nebuliser (1 ml ampoule with white and yellow rings)
Atomizator I-Neb AAD (ampula od 1 ml s bijelim i žutim prstenom)
I-Neb AAD nebuliser:
I-Neb AAD atomizator:
I-Neb nebuliser
Atomizator I-Neb
I. Blood glucose concentrations following a single pre-meal dose of NovoRapid injected immediately before a meal (solid curve) or soluble human insulin administered 30 minutes before a meal (hatched curve) in patients with type 1 diabetes mellitus.
Koncentracije glukoze u krvi nakon jedne doze lijeka NovoRapid primijenjene neposredno prije obroka (puna linija), odnosno otopine humanog inzulina primijenjene 30 minuta prije obroka (isprekidana linija) u bolesnika sa šećernom bolešću tipa 1.
i.m. injection
i.m. injekcija
i.m. use
i.m. primjena
I.V. use
i.v. primjena
I.V. use.
Za i.v. primjenu
I/R IntronA (3 MIU 3 times a week) + ribavirin (1,000/1,200 mg/day)
I/R IntronA (3 milijuna IU triput na tjedan) + ribavirin (1000/1200 mg na dan)
I253S
I253T
I253T
Q250P
ia syndrome
indrom palmarno-plantarne
IAR’s also include atrial fibrillation and anaphylaxis which occur beneath the 0.5% cut for related events (see section 4.4).
Reakcije povezane s infuzijom također uključuju fibrilaciju atrija i anafilaksiju, ali se one javljaju u manje od 0,5% bolesnika, što je određeno kao granična vrijednost iznad koje se nuspojavu smatra povezanom s primjenom lijeka (vidjeti dio 4.4).
IAS-USA lists
IAS-USA liste
Iasibon 1 mg concentrate for solution for infusion
Iasibon 1 mg koncentrat za otopinu za infuziju
Iasibon 2 mg concentrate for solution for infusion
Iasibon 2 mg koncentrat za otopinu za infuziju
Iasibon 2 mg concentrate for solution for infusion ibandronic acid
Iasibon 2 mg koncentrat za otopinu za infuziju ibandronatna kiselina
Iasibon 2mg is supplied as pack containing 1 ampoule (4 ml type I glass ampoule).
Iasibon 2 mg je dostupan u pakiranju od 1 ampule (ampula od 4 ml, staklo tipa I).
Iasibon 50 mg film coated tablets
Iasibon 50 mg filmom obložene tablete
Iasibon 50 mg film coated tablets are supplied in Polyamide/Al/PVC - Aluminum foil blister with 3, 6, 9, 28 or 84 tablets, packaged in a cardboard box.
Iasibon 50 mg filmom obložene tablete dolaze u blisterima od poliamid/Al/PVC – aluminijske folije s 3, 6, 9, 28 ili 84 tablete, pakiranima u kartonsku kutiju.
Iasibon 6 mg concentrate for solution for infusion
Iasibon 6 mg koncentrat za otopinu za infuziju
Iasibon 6mg is supplied as packs containing 1, 5 and 10 vials (9 ml type I glass vial with a bromobutyl rubber stopper).
Iasibon 6mg je dostupan u pakiranju od 1, 5 i 10 bočice (bočica od 9 ml, staklo tipa I).
Iasibon concentrate for solution for infusion should be administered as an intravenous infusion.
Iasibon koncentrat za otopinu za infuziju treba primijeniti kao intravensku infuziju .
Iasibon concentrate for solution for infusion should be administered as an intravenous infusion.
Iasibon koncentrat za otopinu za infuziju treba primijeniti kao intravensku infuziju.
Iasibon contains less than 1 mmol sodium (23 mg) per ampoule, i.e. essentially sodium free.
Iasibon sadrži manje od 1 mmol natrija (23 mg) po ampuli, odnosno bitno natrij besplatno
Iasibon contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially sodium free.
Iasibon sadrži manje od 1 mmol natrija (23 mg) po ampuli, odnosno bitno natrij besplatno
Iasibon contains the active substance ibandronic acid.
Iasibon sadrži djelatnu tvar, ibandronatnu kiselinu.
Iasibon is a colourless, clear solution.
Iasibon je bezbojna, bistra otopina.
Iasibon is a ‘generic medicine’.
Iasibon je „generički lijek”.
Iasibon is indicated in adults for
Iasibon je indiciran u odraslih za:
Iasibon is indicated in adults for:
Iasibon je indiciran u odraslih za:
Iasibon is normally given by a doctor or other medical staff who have experience with the treatment of cancer.
Iasibon će Vam obično dati liječnik ili drugi zdravstveni djelatnici koji imaju iskustva u liječenju raka..
Iasibon is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases’)
Iasibon se koristi za lijiečenje odraslih bolesnika i biti će Vam propisan ako imate rak dojke koji se proširio na kosti (što se naziva „koštane metastaze“).
Iasibon is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases’).
Iasibon se koristi za lijiečenje odraslih bolesnika i biti će Vam propisan ako imate rak dojke koji se proširio na kosti (što se naziva „koštane metastaze“).
Iasibon is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases’).
Iasibon se koristi za ljiečenje odraslih bolesnika i biti će Vam propisan ako imate rak dojke koji se proširio na kosti (što se naziva „koštane metastaze“).
Iasibon should not be used during breast feeding.
Iasibon se ne smije koristiti za vrijeme dojenja.
Iasibon should not be used during breat-feeding.
Iasibon se ne smije koristiti za vrijeme dojenja.
Iasibon should not be used in children and adolescents below the age of 18 years.
Iasibon se ne smije davati djeci i adolescentima mlađim od 18 godina.
Iasibon should not be used in children and adolescentsbelow the age of 18 years.
Iasibon se ne smije davati djeci i adolescentima mlađim od 18 godina.
Iasibon tablets contain lactose and should not be administered to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Iasibon tablete sadrže laktozu i ne smiju se davati bolesnicima s rijetkim nasljednim poremećajima nepodnošenja galaktoze, deficijencije Lapp laktaze ili malapsorpcije glukoze-galaktoze.
Iasibon therapy should only be initiated by physicians experienced in the treatment of cancer.
Liječenje lijekom Iasibon smiju započeti samo liječnici s iskustvom u liječenju zloćudnih bolesti.
IB Biomedical Corporation of Quebec doing business as GlaxoSmithKline Biologicals North America
IB Biomedical Corporation of Quebec koja djeluje kao GlaxoSmithKline Biologicals North America
IBA Molecular Italy S.R.L., Monza, Italy
IBA Molecular Italy S.R.L., Monza, Italija
IBA Molecular Italy S.R.L., Rome, Italy
IBA Molecular Italy S.R.L., Rome, Italija
IBA Molecular Italy S.R.L., Udine, Italy
IBA Molecular Italy S.R.L., Udine, Italija
IBA Molecular Spain, S.A., Madrid, Spain
IBA Molecular Spain, S.A., Madrid, Španjolska
IBA Molecular Spain, S.A., Seville, Spain
IBA Molecular Spain, S.A., Seville, Španjolska
Ibandronate works by reducing the amount of calcium that is lost from your bones.
Iasibon djeluje tako da smanjuje gubitak kalcija iz kostiju.
Ibandronatebandro nate 6 mg
ibandronat 6 mg n=154
Ibandronatebandronat e 50 mg n=287
ibandronat 50 mg n=287
Ibandronic acid 2.5 mg daily tablets
Ibandronatna kiselina 2,5mg tablete jedanput dnevno
Ibandronic acid 3 mg injection every 3 months
Injekcija ibandronatne kiseline od 3mg svaka tri mjeseca
ibandronic acid 3 mg injection every 3 months (N=334)
Injekcija ibandronatne kiseline od 3mg svaka 3 mjeseca (N=334)
ibandronic acid 3 mg injection every 3 months (N=365)
Injekcija ibandronatne kiseline od 3mg svaka 3 mjeseca (N=365)
Ibandronic acid 50 mg n=287
Ibandronatna kiselina 50 mg
Ibandronic acid Accord 2 mg concentrate for solution for infusion
Ibandronic acid Accord 2 mg koncentrat za otopinu za infuziju
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe
Ibandronic acid Accord 3 mg otopina za injekciju u napunjenoj štrcaljki
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringe should be injected intravenously over a period of 15 - 30 seconds.
Ibandronic acid Accord 3 mg otopina za injekciju u napunjenoj štrcaljki injicira se intravenski u trajanju od 15 do 30 sekundi.
Ibandronic acid Accord 3 mg solution for injection in pre-filled syringes is a clear colourless solution.
Ibandronic acid Accord 3 mg otopina za injekciju u napunjenoj štrcaljki bistra je i bezbojna otopina.
Ibandronic acid Accord 3 mg solutionfor injection (for osteoporosos indications): Medicinal product subject to medical prescription.
Ibandronic acid Accord 3 mg otopina za injekciju (za indikacije osteoporoze): lijek se izdaje na recept.
Ibandronic acid Accord 6 mg concentrate for solution for infusion
Ibandronic acid Accord 6 mg koncentrat za otopinu za infuziju
Ibandronic acid Accord concentrate for solution for infusion should be administered as an intravenous infusion.
Ibandronic acid Accord koncentrat za otopinu za infuziju treba primijeniti kao intravensku infuziju.
Ibandronic acid Accord contains less than 1 mmol sodium (23 mg) per dose (3 ml), i.e. essentially “sodium-free”.
Ibandronic acid Accord sadrži manje od 1 mmol natrija (23 mg) po dozi (3 ml), odnosno zanemarive količine natrija.
Ibandronic Acid Accord contains less than 1 mmol sodium (23 mg) per vial, i.e. ‘essentially sodium free’.
Ibandronic acid Accord sadrži manje od 1 mmol natrija (23 mg) po bočici, odnosno zanemarive količine natrija.
Ibandronic acid Accord is a colourless, clear solution.
Ibandronic acid Accord je bezbojna, bistra otopina.
Ibandronic acid Accord is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases’).
Ibandronic acid Accord se koristi za liječenje odraslih bolesnika i bit će Vam propisan ako imate rak dojke koji se proširio na Vaše kosti (što se naziva „koštane metastaze“).
Ibandronic acid Accord is usually administered in a hospital setting.
Ibandronic acid Accord se obično primjenjuje u bolničkim uvjetima.
Ibandronic acid Accord may reverse bone loss by stopping more loss of bone and increasing bone mass in most women who take it, even though they won’t be able to see or feel a difference.
Ibandronic acid Accord može zaustaviti gubitak kosti sprečavajući veći gubitak kosti i povećavajući masu kosti u većine žena koje je primjenjuju, čak i ako ne vide ili osjećaju razliku.
Ibandronic acid Accord must not be used in children or adolescents below 18 years.
Ibandronic acid Accord se ne smije davati djeci ni adolescentima mlađima od 18 godina.
Ibandronic acid Accord should not be used in children and adolescents below the age of 18 years.
Ibandronic acid Accord se ne smije davati djeci i adolescentima mlađim od 18 godina.
Ibandronic acid injection is essentially sodium free.
Injekcija ibandronatne kiseline sadrži zanemarive količine natrija.
Ibandronic acid is indicated in adults for
Ibandronatna kiselina je indicirana u odraslih za
Ibandronic acid is removed from the circulation via bone absorption (estimated to be 40 – 50 % in postmenopausal women) and the remainder is eliminated unchanged by the kidney.
Apsorbirani udio ibandronatne kiseline uklanja se iz cirkulacije koštanom apsorpcijom (što je procijenjeno na 40-50% u žena u postmenopauzi), a ostatak se nepromijenjen eliminira putem bubrega.
Ibandronic Acid Sandoz
Ibandronatna kiselina Sandoz
Ibandronic acid Sandoz 50 mg
Ibandronatna kiselina Sandoz 50 mg
Ibandronic acid Sandoz 50 mg film-coated tablets
Ibandronatna kiselina Sandoz 50 mg filmom obložene tablete
Ibandronic acid Sandoz 50 mg film-coated tablets are supplied in Polyamide/Al/PVC - Aluminium foil blister with 3, 6, 9, 28 or 84 tablets, packaged in a cardboard box.
Ibandronatna kiselina Sandoz 50 mg, filmom obložene tablete pakirane su u poliamid/Al/PVC - aluminijska folija blistere s 3, 6, 9, 28 ili 84 tablete u kartonskoj kutiji.
Ibandronic Acid Sandoz is a ‘generic medicine’.
Ibandronatna kiselina Sandoz je „generički lijek”.
Ibandronic Acid Sandoz is used to prevent ‘skeletal events’ (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).
Ibandronatna kiselina Sandoz koristi se za sprječavanje "skeletnih poremećaja" (fraktura [slomljenih kostiju] ili koštanih komplikacija koje zahtijevaju liječenje) u bolesnika s rakom dojke i metastazama u kostima (ako se rak proširio u kosti).
Ibandronic acid Sandoz should not be used in children and adolescents below the age of 18 years.
Ibandronatna kiselina Sandoz ne smije se davati djeci i adolescentima mlađim od 18 godina.
Ibandronic acid should not be used during breast-feeding.
Ibandronatna kiselina se ne smije koristiti za vrijeme dojenja.
Ibandronic acid should not be used during breastfeeding.
Ibandronatna kiselina se ne smije koristiti tijekom dojenja.
Ibandronic Acid Teva 150 mg film-coated tablets
Ibandronatna kiselina Teva 150 mg filmom obložene tablete
Ibandronic Acid Teva 150 mg film-coated tablets ibandronic acid
Ibandronatna kiselina 150 mg filmom obložene tablete ibandronatna kiselina
Ibandronic Acid Teva 150 mg film-coated tablets ibandronic acid
Ibandronatna kiselina Teva 150 mg filmom obložene tablete ibandronatna kiselina
Ibandronic Acid Teva 50 mg film-coated tablets
Ibandronatna kiselina Teva 50 mg filmom obložene tablete